Syros Pharmaceuticals (SYRS)
(Delayed Data from NSDQ)
$5.51 USD
+0.08 (1.47%)
Updated May 15, 2024 04:00 PM ET
After-Market: $5.53 +0.02 (0.36%) 7:54 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.51 USD
+0.08 (1.47%)
Updated May 15, 2024 04:00 PM ET
After-Market: $5.53 +0.02 (0.36%) 7:54 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Zacks News
Can Illumina (ILMN) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Illumina Inc. (ILMN), a leading provider of tools and integrated systems for analysis of genetic variation and function, is scheduled to report first-quarter 2017 financial results on Apr 25, after the closing bell.
Integra LifeSciences (IART) Q1 Earnings: A Beat in Store?
by Zacks Equity Research
We expect Integra LifeSciences Holdings Corporation (IART) to beat expectations when it reports its first-quarter 2017 results, after market close on Apr 26.
GNC Holdings (GNC) Q1 Earnings: Disappointment in Store?
by Zacks Equity Research
GNC Holdings, Inc. (GNC) -- a specialty retailer of health and nutrition related products -- is scheduled to report first-quarter 2017 financial results on Apr 18, before the opening bell.
What's in Store for Walgreens Boots (WBA) in Q2 Earnings?
by Zacks Equity Research
Walgreens Boots Alliance, Inc (WBA) is slated to release second-quarter 2017 results, before the market opens on Apr 5.
Can Syros Pharmaceuticals (SYRS) Run Higher on Strong Earnings Estimate Revisions?
by Anupama Mukhopadhyay
Syros Pharmaceuticals (SYRS) seems to be a compelling pick on the back of its solid estimate revisions both in the current year and the current quarter.
Can The Uptrend Continue for Syros Pharmaceuticals (SYRS)?
by Zacks Equity Research
Investors certainly have to be happy with Syros Pharmaceuticals Inc (SYRS) and its short term performance
Syros Pharmaceuticals Stock: 3 Reasons Why SYRS Is a Top Choice for Momentum Investors
by Zacks Equity Research
Let's focus on Syros Pharmaceuticals, Inc. (SYRS) as this momentum stock is looking especially impressive right now.